The phosphorylation dependent binding of arrestins to cytoplasmic domains of G-protein coupled receptors (GPCRs) is thought to be a crucial step in receptor desensitization. In some GPCR systems, arrestins have also been demonstrated to be involved in receptor internalization, resensitization, and the activation of signaling cascades. The objective of the current study was to examine binding interactions of members of the arrestin family with the formyl-peptide receptor (FPR), a member of the GPCR family of receptors. Peptides representing the unphosphorylated and phosphorylated carboxy terminus of the FPR were synthesized and bound to polystyrene beads via a biotin/streptavidin interaction. Using fluorescein-conjugated arrestins, binding interactions between arrestins and the bead-bound FPR carboxy terminus were analyzed by flow cytometry. Arrestin2 and arrestin3 bound to the FPR carboxy terminus peptide in a phosphorylation-dependent manner, with K d values in the µM range. Binding of visual arrestin, which binds rhodopsin with high selectivity, was not observed. Arrestin2 (1-382) and arrestin3 (1-393), truncated mutant forms of arrestin that display phosphorylation-independent binding to intact receptors, were also observed to bind the beadbound FPR terminus in a phosphorylation-dependent manner, but with much greater affinity than the full length arrestins, yielding K d values in the 5-50 nM range. Two additional arrestin mutants, which are full length but display phosphorylation-independent binding to intact GPCRs, were evaluated for their binding affinity to the FPR carboxy terminus. Whereas the single point mutant, arrestin2 R169E, displayed an affinity similar to that of the full length arrestins, the triple point mutant, arrestin2 I386A/V387A/F388A, displayed an affinity more similar to that of the truncated forms of arrestin. The results suggest that the carboxy terminus of arrestin is a critical determinant in regulating the binding affinity of arrestin for the phosphorylated domains of GPCRs.
Introduction
G protein-coupled receptors (GPCRs 2 ) are the largest family of cellular surface receptors, the mediators of numerous physiological responses, and the targets of approximately 50% of theraputic drugs (1) . Their activation occurs through the binding of specific ligands to the extracellular face of the receptor, whereas cellular activation is mediated through interactions with cytoplasmic proteins, such as G proteins. Following ligand-mediated activation, GPCRs are the target of regulatory mechanisms aimed initially at terminating and then at reinitiating the signaling capacity of the cell.
Furthermore, GPCR processing has also been shown to be important in the activation of Src and certain MAP kinase pathways (2) . The protein arrestin was first characterized as a protein involved in GPCR desensitization following receptor phosphorylation, but has has recently been demonstrated to play multiple roles in receptor function, including acting as an adapter for clathrin-mediated endocytosis and a scaffolding protein for MAP kinase cascade components (3) . In light of our expanding knowledge of arrestin's many diverse functions, it is clear that a greater understanding of its interactions with GPCRs is essential.
Arrestins comprise a family of four known members in mammals: two visual arrestins, 1 and 4, found in the rod and cone cells of the retina, and two non-visual arrestins, 2 and 3, which are found in most other tissues of the body (4). The 2.8 Å crystal structure of visual arrestin (5) and 1.9 Å crystal structure of arrestin2 (6) both indicate that arrestin exists as a bipartite molecule consisting of by guest on http://www.jbc.org/ Downloaded from two seven stranded beta sandwiches with a network of hydrogen-bonded charged residues forming what has been described as a polar core (5) . The current model of arrestin-mediated interactions with ligand-occupied GPCRs holds that after ligand occupancy, cytoplasmic regions of the receptor are phosphorylated at serine and threonine residues by a member of the family of G protein-coupled receptor kinases (7) . Upon arrestin binding, these phosphorylated residues disrupt arrestin's polar core, inducing a conformational change within the molecule that allows it to interact further with the receptor (8) . This model proposes that arrestin binding to the receptor blocks further receptor interactions with G proteins, presumably by steric inhibition, thus preventing further G proteinmediated cellular activation (9) .
Recent studies have shown that arrestins play roles in receptor signaling other than desensitization. Arrestin has been shown to act as an adapter protein that interacts with the clathrin adapter AP-2 as well as with clathrin itself, leading to the internalization of some arrestin bound receptors via clathrin coated pits (10, 11) . Arrestin has also been suggested to determine the rate of resensitization and re-expression of receptors based upon the rate of its dissociation from internalized receptor (12, 13) . However, one of the more recent observations made of arrestin has been the discovery that arrestins act as scaffolding proteins in some mitogen activated protein kinase (MAPK) cascades, specifically in cascades leading to JNK3 and ERK2 activation (14) (15) (16) (17) . These studies have elevated arrestin's role in receptor signaling from a desensitizing agent to an active and multipurpose participant in signal transduction.
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Despite the importance of arrestin-GPCR interactions, little is known about the receptor domains and mechanisms involved in arrestin binding. Mutagenesis experiments have defined regions of arrestin involved in recognizing the phosphorylation status as well as the activation status (i.e. whether or not ligand is bound) of the receptor (6, 8, 18, 19) . Swapping of carboxy terminal domains between GPCRs has also indicated that the pattern of receptor phosphorylation in this domain can affect rates of receptor internalization and recycling/resensitization (13) . We have been examining mechanisms of receptor activation, desensitization and internalization using the N-formyl peptide receptor (FPR), a member of the chemoattractant/chemokine family of receptors (20, 21) .
Our results have demonstrated that receptor phosphorylation is critical in arrestin binding (22, 23) , as is the presence of the highly conserved "DRY" motif (24) . Arrestin interactions with the FPR are, however, not required for FPR internalization or the prevention of G protein binding, as we have recently demonstrated that receptor phosphorylation alone can be sufficient to block G protein interactions in the absence of arrestin (22, 23) . These results suggest that the primary roles of arrestin in certain GPCR systems may in fact be to act as an adapter and a scaffold.
In this study, we examined the interactions between members of the arrestin family with the phosphorylated carboxy terminal domain of the FPR using a bead-based, cell-free assay. Biotinylated peptides were synthesized that represent the 47 residues of the FPR carboxy terminus in both a phosphorylated and unphosphorylated state and bound to streptavidin-coated, polystyrene beads that were then incubated with fluorescein-conjugated arrestins and analyzed by flow cytometry to assess 
Experimental Procedures
Materials -Streptavidin-coated 6.2 µm beads were purchased from Spherotech, Inc. Chicken anti-FPR carboxy terminus (generated from a peptide representing the carboxy-terminal 10 amino acids of the receptor) and Goat anti-Chicken-FITC antibodies were purchased from Aves Lab, Inc.
Alkaline phosphatase (E. coli), protease inhibitor cocktail 1 and phosphatase inhibitor were purchased from CalBiochem, Inc. NHS-fluorescein was purchased from Pierce and Molecular Probes.
Plasticware was obtained from VWR Scientific. All other reagents were purchased from Sigma.
Arrestin proteins were expressed in E. coli (strain BL21) and purified by sequential heparinSepharose and Q-Sepharose chromatography essentially as described (25). Isolation of the carboxy terminus of the FPR was provided by synthetic peptides that duplicate the carboxy terminal 47 amino acid sequence of the FPR (Fig. 1A ). These peptides were synthesized both as an unphosphorylated 47 amino acid peptide (hereafter referred to as 47mer) and a phosphorylated version of that peptide, containing phosphoserine or phosphothreonine residues at 4 sites (thr329, thr331, thr336 and ser338) (hereafter referred to as phospho47mer, Fluorescence associated with the 47mer-coated beads was similar to that observed with beads coated with biotinylated FLAG peptide or free biotin, suggesting that there was no specific binding to the unphosphorylated carboxy terminal peptide. To determine whether the high level of bead-associated fluorescence was indeed due to specific arrestin2-FITC binding, phospho47mer coated beads were preincubated with excess unlabeled arrestin2 before incubation with arrestin2-FITC. In this instance, fluorescence was reduced to the level seen with 47mer-coated, FLAG-coated, and biotin blocked beads (Fig. 3b) . These results indicate arrestin2 binds the FPR carboxy terminal peptide on beads in a phosphorylation dependent manner, consistent with our observations of arrestin2 binding to intact FPR in live cells (22, 24) and in vitro (23) .
The possibility existed that the unphosphorylated and phosphorylated 47mer peptides assume fundamentally different conformations in solution due to folding during the synthesis or rehydration of the lyophilized peptides. Secondary structure considerations can be of particular relevence in peptides with lengths greater than 35-40 amino acids. To test for this, phospho47mer peptide was bound to streptavidin beads and then treated with alkaline phosphatase, the assumption being that this treatment would result in dephosphorylation without a major refolding of the peptide's secondary structure. Subsequent treatment of the beads with a mixture of mouse anti-phosphoserine-FITC and mouse anti-phosphothreonine-FITC showed that alkaline phosphatase treatment of bead-bound phospho47mer resulted in an almost complete loss of serine and threonine phosphorylation (Fig. 4) .
Similarly, alkaline phosphatase treatment of phospho47mer coated beads followed by incubation with Because of the relatively low affinity (Fig. 6 ) and stability (data not shown) of the full length arrestin2-FITC, we elected to carry out subsequent competition binding assays using the flouresceinated arrestin3 values of 5 nM and 62 nM, respectively. These results confim that both truncated versions of arrestin display significantly higher affinities for the phospho47mer than the full length proteins. Arrestin2
(1-382) exhibits a 100-fold higher affinity than its full length counterpart, whereas arrestin3 (1-393) exhibits a 5-fold higher affinity than its full length counterpart.
In addition to truncated arrestin proteins exhibiting phosphorylation-independent binding to GPCRs, mutant forms of full length arrestin have been characterized which also demonstrate the ability to bind to GPCRs in their activated but unphosphorylated state. Two such mutants are the single point mutant arrestin2 R169E and the triple point mutant arrestin2 3A (I386A/V387A/F388A) (34). These proteins have been shown to display similar properties to the truncated proteins. To test whether these mutants exhibited low affinity like the full length arrestin proteins or high affinity like the phosphorylated-independent truncated arrestin proteins, we performed competition binding assays using the flouresceinated arrestin3 (1-393) as the reporter (Fig. 10) The carboxy terminus of the FPR used in this study was isolated by the use of biotinylated synthetic peptides having the same sequence as the FPR carboxy terminus, in either a phosphorylated or unphosphorylated state. One clear advantage of using synthetic phosphorylated peptides, as opposed to biologically isolated receptor domains, is the magnitude and uniformity with which the peptide is phosphorylated. These peptides were bound to streptavidin-coated polystyrene beads in a Our results demonstrated that fluorescently-labeled arrestins could specifically bind to the phosphorylated carboxy terminal FPR peptide. This was seen as a complete lack of binding to the unphosphorylated peptide as well as to a negatively charged FLAG peptide (DYKDDDDK-biotin).
Thus, it was not simply the presence of a negatively charged peptide on the bead surface that resulted in binding. Furthermore, in order to rule out that the lack of arrestin binding to the synthetic unphosphorylated peptide was not a result of a conformational effect from the synthesis, we enzymatically dephosphorylated the phosphorylated peptide and showed that the binding of arrestin could be completely eliminated. Selectivity among arrestin variants was also demonstrated in that only arrestin2 and arrestin3, but not visual arrestin, were able to bind to the phosphorylated peptide.
Furthermore, in a soluble receptor system previously used by our lab to study FPR arrestin interactions, preincubation with arrestin of the phosphorylated but not the unphosphorylated peptide was able to successfully compete with intact phosphorylated receptor for arrestin binding. It has been demonstrated that truncated forms of arrestins bind to GPCRs in a phosphorylation-independent, but ligand-and activation-dependent manner (20, 33) . There is also evidence that truncated forms of arrestin bind with higher affinity to phosphorylated GPCRs than do the full length arrestins (12, 33) . The carboxy terminus of arrestins may constitute a steric hindrance to receptor binding with a rearrangement of the the protein being necessary for binding. It has been
proposed that truncated arrestins bind with high affinity due, at least in part, to the elimination of one step in the multistep process of arrestin binding (19) . Recent in vivo studies show that, upon addition of agonist, truncated arrestin2 begins translocating from the cytoplasm to the membrane sooner than full-length arrestin2, and that this translocation occurs more rapidly and to a greater extent than seen with full-length arrestin (12) . Moreover, in these studies truncated arrestin2 remained co-localized with receptor longer than full-length arrestin2. Our results demonstrate not only that truncated forms of arrestin discriminate between the phosphorylated and unphosphorylated forms of the carboxy terminal FPR peptide but also that they bind with substantially higher affinity to the phosphopeptide than do the full length arrestins. This suggests that the major site(s) of interaction between the truncated forms of arrestins and unphosphorylated GPCRs may be regions other than the carboxy terminus. We have described one such possible site as the highly conserved "DRY" sequence of the second intracellular loop of all GPCRs (24) . This site is believed to be critical in conveying the This subsequently results in a dislodging of residues that are part of the polar core (eg. R382) (34).
Our binding assays indicate that, in terms of binding affinity, arrestin2 R169E behaves more like fulllength arrestin2, while arrestin2 3A behaves more like truncated arrestin2. Although it is believed that the R169E mutant stabilizes the active state of arrestin, it is likely that the lower affinity of the R169E mutant is a result of the fact that this mutated residue is located in the polar core where it is believed to be a counter-ion for the receptor phosphates. This suggests that other receptor recognition sites within arrestin compensate for this defect when interacting with the whole receptor as compared to the phosphorylated carboxy terminal domain. However, in the case of the arrestin 3A mutant, as in the case of the truncated mutants, the polar core remains intact and can bind the phosphopeptide with high affinity. These conclusions are supported by mechanistic considerations of arrestin binding (34) and helps to explain the observations of Oakley and coworkers (12) .
In this study, we have examined the role played by the FPR carboxy terminus in arrestin binding interactions utilizing a novel bead-based cytometric assay. We have demonstrated an absolute binding dependence on receptor peptide phosphorylation for both full length and truncated arrestin variants, with the truncated variants displaying substantially higher affinities. Furthermore, a full length, phosphorylation-independent arrestin lacking mutations in the polar core (arrestin2 3A)
was capable of exhibiting high phosphopeptide affinity, suggesting that a critical step in the activation of arrestin is the displacement of the arrestin carboxy terminus from the core of the protein. Arr2 R169E Arr2 3A
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